IDEXX Laboratories (IDXX) Financials

$517.16 -4.52 (-0.87%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$514.52 -2.64 (-0.51%)

As of 08:39 AM Eastern

Annual Income Statements for IDEXX Laboratories

This table shows IDEXX Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	888	845	679	745	582	428	377	263	222	192
Consolidated Net Income / (Loss)	888	845	679	745	582	428	377	263	222	192
Net Income / (Loss) Continuing Operations	888	845	679	745	582	428	377	263	222	192
Total Pre-Tax Income	1,110	1,061	860	903	662	522	458	381	322	273
Total Operating Income	1,128	1,097	899	932	695	553	491	413	350	300
Total Gross Profit	2,379	2,190	2,004	1,889	1,571	1,366	1,242	1,097	975	890
Total Revenue	3,898	3,661	3,367	3,215	2,707	2,407	2,213	1,969	1,775	1,602
Operating Revenue	3,898	3,661	3,367	3,215	2,707	2,407	2,213	1,969	1,775	1,602
Total Cost of Revenue	1,519	1,471	1,363	1,326	1,136	1,041	972	872	800	712
Operating Cost of Revenue	1,519	1,471	1,363	1,326	-	1,041	972	872	-	712
Total Operating Expenses	1,251	1,093	1,106	957	877	813	750	684	625	590
Selling, General & Admin Expense	442	336	326	310	301	261	245	221	207	183
Marketing Expense	589	566	525	487	434	418	387	354	317	300
Research & Development Expense	220	191	255	161	141	133	118	109	101	100
Total Other Income / (Expense), net	-19	-36	-39	-29	-33	-31	-34	-32	-28	-27
Interest Expense	31	42	40	30	33	31	35	37	32	29
Interest & Investment Income	13	5.63	1.07	0.43	0.59	0.43	1.15	5.25	3.66	2.47
Income Tax Expense	222	216	181	158	80	94	81	118	100	81
Basic Earnings per Share	$10.77	$10.17	$8.12	$8.74	$6.82	$4.97	$4.34	$3.00	$2.47	$2.07
Weighted Average Basic Shares Outstanding	82.47M	83.07M	83.62M	85.20M	85.34M	86.12M	86.86M	87.77M	89.73M	92.60M
Diluted Earnings per Share	$10.67	$10.06	$8.03	$8.60	$6.71	$4.89	$4.26	$2.94	$2.44	$2.05
Weighted Average Diluted Shares Outstanding	83.25M	83.98M	84.60M	86.57M	86.72M	87.54M	88.47M	89.57M	90.88M	93.65M
Weighted Average Basic & Diluted Shares Outstanding	81.33M	83.09M	82.90M	84.25M	85.43M	85.33M	86.90M	87.70M	89.90M	92.80M

This table shows IDEXX Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	243	216	233	203	236	195	212	224	214	172	181
Consolidated Net Income / (Loss)	243	216	233	203	236	195	212	224	214	172	181
Net Income / (Loss) Continuing Operations	243	216	233	203	236	195	212	224	214	172	181
Total Pre-Tax Income	310	256	299	259	295	240	268	286	268	213	234
Total Operating Income	317	262	304	264	299	245	275	296	280	227	245
Total Gross Profit	623	571	596	619	593	526	548	573	543	485	507
Total Revenue	998	954	976	1,004	964	902	916	944	900	829	842
Operating Revenue	998	954	976	1,004	964	902	916	944	900	829	842
Total Cost of Revenue	375	384	380	384	371	375	368	371	357	344	335
Operating Cost of Revenue	375	384	380	384	371	375	368	371	357	344	335
Total Operating Expenses	307	309	292	355	294	281	273	277	263	258	262
Selling, General & Admin Expense	92	101	92	157	92	87	89	90	70	83	84
Marketing Expense	156	150	146	143	149	142	136	141	148	132	130
Research & Development Expense	59	58	54	55	53	52	48	47	45	43	48
Total Other Income / (Expense), net	-6.45	-5.30	-4.98	-4.75	-3.48	-5.63	-7.39	-10	-13	-13	-11
Interest Expense	7.67	7.50	7.70	8.10	7.91	9.27	8.65	11	13	14	11
Interest & Investment Income	1.22	2.20	2.71	3.35	4.43	3.63	1.26	0.33	0.42	0.24	0.35
Income Tax Expense	67	40	66	56	60	45	56	62	54	41	53
Basic Earnings per Share	$2.98	$2.64	$2.83	$2.46	$2.84	$2.34	$2.55	$2.70	$2.58	$2.08	$2.17
Weighted Average Basic Shares Outstanding	81.32M	82.47M	82.30M	82.63M	83.10M	83.07M	83.10M	83.09M	82.99M	83.62M	83.25M
Diluted Earnings per Share	$2.96	$2.62	$2.80	$2.44	$2.81	$2.31	$2.53	$2.67	$2.55	$2.05	$2.15
Weighted Average Diluted Shares Outstanding	81.92M	83.25M	83.06M	83.39M	83.96M	83.98M	83.99M	83.98M	83.96M	84.60M	84.11M
Weighted Average Basic & Diluted Shares Outstanding	80.42M	81.33M	81.88M	82.31M	82.59M	83.09M	83.05M	83.01M	83.00M	82.90M	82.82M

This table details how cash moves in and out of IDEXX Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-166	341	-32	-239	294	-33	-59	33	26	-194
Net Cash From Operating Activities	929	907	543	756	648	459	400	373	354	222
Net Cash From Continuing Operating Activities	929	907	543	756	648	459	400	373	354	222
Net Income / (Loss) Continuing Operations	888	845	679	745	582	428	377	263	222	192
Consolidated Net Income / (Loss)	888	845	679	745	582	428	377	263	222	192
Depreciation Expense	130	115	112	105	96	88	83	83	78	69
Non-Cash Adjustments To Reconcile Net Income	67	67	58	44	38	41	29	25	23	19
Changes in Operating Assets and Liabilities, net	-156	-120	-306	-138	-68	-98	-90	1.47	29	-60
Net Cash From Investing Activities	-207	-125	-195	-293	-109	-206	139	-139	-91	-308
Net Cash From Continuing Investing Activities	-207	-125	-195	-293	-109	-206	139	-139	-91	-308
Purchase of Property, Plant & Equipment	-121	-134	-149	-120	-107	-155	-116	-74	-65	-83
Acquisitions	-87	0.00	-22	-173	-2.17	-51	-30	-17	-1.96	-10
Sale and/or Maturity of Investments	1.56	8.38	0.00	0.00	-	-	284	287	204	57
Other Investing Activities, net	-1.00	0.00	-25	0.00	-0.25	-	-	-	-	-
Net Cash From Financing Activities	-878	-442	-371	-697	-248	-286	-598	-208	-237	-101
Net Cash From Continuing Financing Activities	-878	-442	-371	-697	-248	-286	-598	-208	-237	-101
Repayment of Debt	-75	-75	-75	-53	-295	-110	-256	44	38	23
Repurchase of Common Equity	-837	-72	-820	-747	-183	-302	-369	-283	-304	-402
Issuance of Debt	0.00	-329	506	74	200	100	0.00	0.00	-	250
Issuance of Common Equity	44	47	36	47	51	36	38	39	38	22
Other Financing Activities, net	-11	-13	-17	-17	-22	-10	-11	-8.07	-4.37	5.88
Other Net Changes in Cash	-9.53	2.13	-8.61	-4.64	-	-	-	6.20	-	-

This table details how cash moves in and out of IDEXX Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-124	-20	-93	4.16	-56	122	199	21	-1.18	13	-15
Net Cash From Operating Activities	238	262	220	248	199	250	272	200	184	173	189
Net Cash From Continuing Operating Activities	238	262	220	248	199	250	272	200	184	173	189
Net Income / (Loss) Continuing Operations	243	216	233	203	236	195	212	224	214	172	181
Consolidated Net Income / (Loss)	243	216	233	203	236	195	212	224	214	172	181
Depreciation Expense	34	34	34	32	30	30	29	28	28	29	29
Non-Cash Adjustments To Reconcile Net Income	18	16	39	-4.09	16	17	17	17	16	14	15
Changes in Operating Assets and Liabilities, net	-56	-3.88	-86	17	-83	8.80	14	-69	-75	-41	-35
Net Cash From Investing Activities	-30	-40	-27	-33	-107	-30	-28	-27	-40	-49	-49
Net Cash From Continuing Investing Activities	-30	-40	-27	-33	-107	-30	-28	-27	-40	-49	-49
Purchase of Property, Plant & Equipment	-30	-29	-28	-33	-30	-33	-34	-27	-40	-49	-38
Acquisitions	0.00	-10	0.31	-	-77	-	-	-	0.00	-	-12
Sale and/or Maturity of Investments	0.42	0.42	0.42	0.40	0.33	2.12	6.26	-	0.00	-	-
Net Cash From Financing Activities	-330	-233	-291	-210	-144	-102	-43	-151	-146	-117	-149
Net Cash From Continuing Financing Activities	-330	-233	-291	-210	-144	-102	-43	-151	-146	-117	-149
Repurchase of Common Equity	-401	-246	-221	-216	-155	-37	-35	-	0.00	-74	-173
Issuance of Debt	70	-	-	-	-	-	-14	-	-	-54	22
Issuance of Common Equity	7.19	13	5.00	5.36	21	11	13	10	13	12	4.88
Other Financing Activities, net	-6.12	-0.05	-0.22	-0.08	-10	-1.32	-0.33	-0.08	-11	-0.76	-3.08
Other Net Changes in Cash	-2.33	-9.77	-	-	-4.07	4.66	-2.70	-0.34	0.50	5.89	-6.16

This table presents IDEXX Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	3,293	3,260	2,747	2,437	2,295	1,832	1,537	1,713	1,531	1,475
Total Current Assets	1,400	1,495	1,101	956	1,063	680	654	972	846	822
Cash & Equivalents	288	454	113	144	384	90	124	188	155	129
Accounts Receivable	474	457	401	368	331	269	249	235	204	188
Inventories, net	382	380	368	269	210	195	173	164	158	189
Other Current Assets	256	204	220	174	138	125	108	101	91	62
Plant, Property, & Equipment, net	713	702	649	588	555	534	437	379	357	333
Total Noncurrent Assets	1,180	1,062	996	894	677	619	446	362	328	320
Goodwill	405	366	362	359	243	240	214	200	178	179
Intangible Assets	112	85	98	99	53	58	42	44	46	56
Other Noncurrent Operating Assets	664	612	536	436	381	321	190	119	103	85
Total Liabilities & Shareholders' Equity	3,293	3,260	2,747	2,437	2,295	1,832	1,537	1,713	1,531	1,475
Total Liabilities	1,698	1,775	2,138	1,747	1,662	1,655	1,547	1,767	1,639	1,559
Total Current Liabilities	1,068	952	1,236	764	583	725	770	1,005	935	857
Short-Term Debt	418	325	654	148	50	289	399	655	611	573
Accounts Payable	114	111	110	116	75	72	70	67	60	53
Accrued Expenses	502	479	434	459	416	323	261	253	236	206
Current Deferred Revenue	34	37	38	40	43	41	41	29	27	26
Total Noncurrent Liabilities	630	824	902	984	1,079	929	776	763	704	702
Long-Term Debt	450	623	694	775	858	699	601	606	593	597
Noncurrent Deferred Revenue	27	29	31	41	46	49	61	36	33	27
Noncurrent Deferred & Payable Income Tax Liabilities	11	7.24	8.15	8.94	12	33	29	25	39	49
Other Noncurrent Operating Liabilities	142	165	169	158	163	149	85	96	39	29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,595	1,485	609	690	633	178	-9.23	-54	-108	-84
Total Preferred & Common Equity	1,595	1,485	609	690	632	177	-9.51	-54	-108	-84
Total Common Equity	1,595	1,485	609	690	632	177	-9.51	-54	-108	-84
Common Stock	1,691	1,586	1,479	1,394	1,310	1,229	1,153	1,090	1,028	956
Retained Earnings	5,332	4,445	3,600	2,920	2,176	1,596	1,168	804	540	318
Treasury Stock	-5,334	-4,475	-4,392	-3,571	-2,800	-2,601	-2,289	-1,912	-1,633	-1,316
Accumulated Other Comprehensive Income / (Loss)	-94	-71	-78	-53	-54	-46	-42	-36	-43	-42

This table presents IDEXX Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	3,214	3,293	3,351	3,415	3,354	3,260	3,086	2,871	2,808	2,747	2,640
Total Current Assets	1,318	1,400	1,434	1,529	1,502	1,495	1,384	1,179	1,149	1,101	1,059
Cash & Equivalents	164	288	309	402	397	454	332	133	111	113	99
Accounts Receivable	527	474	511	534	507	457	453	462	446	401	388
Inventories, net	396	382	390	380	391	380	394	395	391	368	355
Other Current Assets	230	256	224	213	207	204	206	189	201	220	217
Plant, Property, & Equipment, net	718	713	718	708	709	702	687	683	665	649	612
Total Noncurrent Assets	1,178	1,180	1,199	1,178	1,143	1,062	1,015	1,009	994	996	969
Goodwill	407	405	412	408	409	366	362	364	363	362	355
Intangible Assets	107	112	107	111	115	85	87	91	94	98	100
Other Noncurrent Operating Assets	664	664	680	659	619	612	566	553	536	536	514
Total Liabilities & Shareholders' Equity	3,214	3,293	3,351	3,415	3,354	3,260	3,086	2,871	2,808	2,747	2,640
Total Liabilities	1,766	1,698	1,733	1,835	1,785	1,775	1,789	1,777	1,967	2,138	2,164
Total Current Liabilities	1,136	1,068	1,009	1,117	957	952	970	884	1,066	1,236	1,190
Short-Term Debt	490	418	349	420	325	325	400	339	506	654	633
Accounts Payable	120	114	111	117	117	111	113	108	118	110	110
Accrued Expenses	491	502	511	541	476	479	420	399	404	434	406
Current Deferred Revenue	35	34	38	38	38	37	37	38	38	38	41
Total Noncurrent Liabilities	629	630	723	718	828	824	819	893	902	902	974
Long-Term Debt	450	450	525	525	621	623	619	697	696	694	761
Noncurrent Deferred Revenue	27	27	27	27	28	29	28	29	30	31	35
Noncurrent Deferred & Payable Income Tax Liabilities	8.11	11	5.66	10	8.75	7.24	11	5.57	5.83	8.15	14
Other Noncurrent Operating Liabilities	145	142	166	156	170	165	162	162	169	169	164
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,448	1,595	1,618	1,580	1,569	1,485	1,297	1,094	841	609	476
Total Preferred & Common Equity	1,448	1,595	1,618	1,580	1,569	1,485	1,297	1,094	841	609	476
Total Common Equity	1,448	1,595	1,618	1,580	1,569	1,485	1,297	1,094	841	609	476
Common Stock	1,712	1,691	1,663	1,642	1,621	1,586	1,559	1,531	1,506	1,479	1,453
Retained Earnings	5,575	5,332	5,116	4,883	4,680	4,445	4,250	4,038	3,814	3,600	3,427
Treasury Stock	-5,749	-5,334	-5,085	-4,860	-4,652	-4,475	-4,437	-4,402	-4,402	-4,392	-4,324
Accumulated Other Comprehensive Income / (Loss)	-90	-94	-76	-85	-80	-71	-75	-74	-77	-78	-81

This table displays calculated financial ratios and metrics derived from IDEXX Laboratories' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.46%	8.72%	4.73%	18.79%	12.45%	8.75%	12.40%	10.91%	10.83%	7.81%
EBITDA Growth	3.81%	19.92%	-2.50%	31.13%	23.35%	11.55%	15.79%	15.58%	15.93%	16.03%
EBIT Growth	2.84%	22.07%	-3.57%	34.20%	25.63%	12.52%	18.96%	17.93%	16.78%	15.24%
NOPAT Growth	3.32%	23.10%	-7.72%	25.93%	34.86%	11.90%	41.83%	18.09%	14.54%	9.84%
Net Income Growth	5.07%	24.44%	-8.83%	27.95%	36.08%	13.46%	43.22%	18.56%	15.57%	5.60%
EPS Growth	6.06%	25.28%	-6.63%	28.17%	37.22%	14.79%	44.90%	20.49%	19.02%	14.53%
Operating Cash Flow Growth	2.48%	66.95%	-28.13%	16.59%	41.14%	14.77%	7.18%	5.55%	59.44%	-5.95%
Free Cash Flow Firm Growth	-4.49%	121.22%	-26.86%	-13.50%	115.77%	-10.19%	7.34%	-9.61%	74.04%	-2.44%
Invested Capital Growth	9.91%	7.26%	25.55%	26.95%	7.64%	23.97%	17.95%	4.44%	-5.31%	7.13%
Revenue Q/Q Growth	1.37%	2.04%	0.82%	2.56%	37.32%	-18.99%	1.99%	3.31%	2.50%	3.07%
EBITDA Q/Q Growth	1.64%	1.66%	2.89%	1.69%	9.93%	0.36%	2.98%	3.17%	4.96%	10.45%
EBIT Q/Q Growth	1.47%	1.74%	3.14%	1.54%	11.11%	0.05%	3.70%	3.50%	5.07%	11.99%
NOPAT Q/Q Growth	2.44%	1.90%	2.00%	-1.70%	16.43%	0.92%	14.11%	-4.99%	3.12%	10.31%
Net Income Q/Q Growth	2.50%	2.71%	1.41%	-1.61%	16.96%	1.15%	14.37%	-5.08%	3.73%	10.62%
EPS Q/Q Growth	2.99%	2.65%	2.16%	-1.49%	16.70%	1.66%	14.52%	-7.26%	2.52%	8.47%
Operating Cash Flow Q/Q Growth	1.33%	9.21%	-6.30%	-1.17%	10.87%	4.50%	3.77%	1.54%	11.38%	30.65%
Free Cash Flow Firm Q/Q Growth	3.54%	14.95%	-13.92%	-6.30%	38.87%	-16.27%	-0.42%	-3.42%	18.41%	62.68%
Invested Capital Q/Q Growth	-0.40%	-0.30%	4.17%	0.41%	-0.98%	4.91%	-0.16%	-6.68%	-6.21%	-1.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.04%	59.82%	59.52%	58.76%	58.04%	56.73%	56.10%	55.73%	54.94%	55.58%
EBITDA Margin	32.28%	33.11%	30.01%	32.24%	29.21%	26.63%	25.96%	25.20%	24.18%	23.12%
Operating Margin	28.95%	29.97%	26.69%	28.99%	25.66%	22.97%	22.20%	20.98%	19.73%	18.72%
EBIT Margin	28.95%	29.97%	26.69%	28.99%	25.66%	22.97%	22.20%	20.98%	19.73%	18.72%
Profit (Net Income) Margin	22.78%	23.08%	20.17%	23.17%	21.51%	17.77%	17.04%	13.37%	12.51%	11.99%
Tax Burden Percent	80.00%	79.63%	78.97%	82.52%	87.94%	81.92%	82.37%	69.09%	68.99%	70.34%
Interest Burden Percent	98.36%	96.72%	95.68%	96.85%	95.31%	94.46%	93.16%	92.26%	91.89%	91.07%
Effective Tax Rate	20.00%	20.37%	21.03%	17.48%	12.06%	18.08%	17.63%	30.91%	31.01%	29.66%
Return on Invested Capital (ROIC)	43.47%	45.71%	42.83%	58.56%	54.71%	46.63%	50.51%	39.65%	33.39%	29.35%
ROIC Less NNEP Spread (ROIC-NNEP)	40.71%	42.40%	39.79%	54.84%	50.69%	43.80%	47.19%	36.89%	31.00%	26.67%
Return on Net Nonoperating Assets (RNNOA)	14.19%	35.03%	61.74%	54.06%	88.91%	460.86%	-1,246.06%	-364.56%	-264.44%	1,114.51%
Return on Equity (ROE)	57.66%	80.74%	104.58%	112.62%	143.63%	507.49%	-1,195.55%	-324.91%	-231.06%	1,143.87%
Cash Return on Invested Capital (CROIC)	34.02%	38.70%	20.18%	34.81%	47.35%	25.22%	34.04%	35.31%	38.84%	22.47%
Operating Return on Assets (OROA)	34.44%	36.53%	34.67%	39.39%	33.66%	32.81%	30.23%	25.46%	23.31%	20.98%
Return on Assets (ROA)	27.10%	28.14%	26.20%	31.48%	28.21%	25.39%	23.20%	16.23%	14.78%	13.44%
Return on Common Equity (ROCE)	57.66%	80.74%	104.58%	112.56%	143.44%	505.59%	-1,205.86%	-325.72%	-231.38%	1,136.95%
Return on Equity Simple (ROE_SIMPLE)	55.65%	56.92%	111.56%	107.95%	92.10%	241.05%	-3,963.49%	-486.58%	-204.94%	-228.39%
Net Operating Profit after Tax (NOPAT)	903	874	710	769	611	453	405	285	242	211
NOPAT Margin	23.16%	23.86%	21.08%	23.92%	22.56%	18.82%	18.29%	14.49%	13.61%	13.17%
Net Nonoperating Expense Percent (NNEP)	2.76%	3.31%	3.04%	3.72%	4.02%	2.83%	3.32%	2.76%	2.39%	2.68%
Return On Investment Capital (ROIC_SIMPLE)	36.65%	35.92%	36.26%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	38.96%	40.18%	40.48%	41.24%	41.96%	43.27%	43.90%	44.27%	45.06%	44.42%
SG&A Expenses to Revenue	11.35%	9.17%	9.69%	9.63%	11.11%	10.86%	11.07%	11.22%	11.66%	11.39%
R&D to Revenue	5.64%	5.22%	7.57%	5.01%	5.22%	5.53%	5.33%	5.54%	5.70%	6.22%
Operating Expenses to Revenue	32.09%	29.85%	32.83%	29.78%	32.38%	33.77%	33.90%	34.76%	35.21%	36.85%
Earnings before Interest and Taxes (EBIT)	1,128	1,097	899	932	695	553	491	413	350	300
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,258	1,212	1,011	1,037	791	641	575	496	429	370
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	21.22	31.05	55.50	80.92	67.46	126.22	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	31.39	44.58	226.34	241.06	126.83	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	8.69	12.59	10.03	17.36	15.75	9.31	7.25	6.93	5.92	4.14
Price to Earnings (P/E)	38.13	54.55	49.75	74.96	73.29	52.37	42.55	51.83	47.35	34.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.62%	1.83%	2.01%	1.33%	1.36%	1.91%	2.35%	1.93%	2.11%	2.90%
Enterprise Value to Invested Capital (EV/IC)	15.83	23.55	18.99	38.53	37.30	21.67	19.51	19.62	16.09	10.03
Enterprise Value to Revenue (EV/Rev)	8.83	12.73	10.40	17.61	15.95	9.68	7.64	7.33	6.38	4.66
Enterprise Value to EBITDA (EV/EBITDA)	27.37	38.44	34.65	54.61	54.60	36.35	29.45	29.08	26.38	20.15
Enterprise Value to EBIT (EV/EBIT)	30.52	42.47	38.97	60.74	62.15	42.14	34.43	34.93	32.34	24.88
Enterprise Value to NOPAT (EV/NOPAT)	38.15	53.33	49.35	73.61	70.67	51.44	41.80	50.56	46.87	35.36
Enterprise Value to Operating Cash Flow (EV/OCF)	37.07	51.40	64.50	74.93	66.60	50.74	42.29	38.65	32.03	33.64
Enterprise Value to Free Cash Flow (EV/FCFF)	48.74	62.98	104.73	123.83	81.66	95.11	62.02	56.78	40.29	46.19
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.54	0.64	2.22	1.34	1.44	5.55	-108.34	-23.42	-11.13	-13.93
Long-Term Debt to Equity	0.28	0.42	1.14	1.12	1.36	3.93	-65.13	-11.26	-5.48	-7.11
Financial Leverage	0.35	0.83	1.55	0.99	1.75	10.52	-26.41	-9.88	-8.53	41.79
Leverage Ratio	2.13	2.87	3.99	3.58	5.09	19.99	-51.54	-20.02	-15.64	85.11
Compound Leverage Factor	2.09	2.78	3.82	3.46	4.85	18.88	-48.01	-18.47	-14.37	77.51
Debt to Total Capital	35.23%	38.97%	68.90%	57.24%	58.94%	84.74%	100.93%	104.46%	109.87%	107.73%
Short-Term Debt to Total Capital	16.96%	13.36%	33.42%	9.20%	3.24%	24.78%	40.25%	54.26%	55.75%	52.76%
Long-Term Debt to Total Capital	18.26%	25.61%	35.48%	48.04%	55.70%	59.97%	60.68%	50.20%	54.12%	54.98%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.05%	0.03%	0.03%	0.02%	0.01%	0.01%
Common Equity to Total Capital	64.77%	61.03%	31.10%	42.76%	41.01%	15.23%	-0.96%	-4.48%	-9.89%	-7.75%
Debt to EBITDA	0.69	0.78	1.33	0.89	1.15	1.54	1.74	2.54	2.80	3.16
Net Debt to EBITDA	0.46	0.41	1.22	0.75	0.66	1.40	1.53	1.59	1.89	2.23
Long-Term Debt to EBITDA	0.36	0.51	0.69	0.75	1.09	1.09	1.05	1.22	1.38	1.61
Debt to NOPAT	0.96	1.08	1.90	1.20	1.49	2.18	2.47	4.42	4.98	5.55
Net Debt to NOPAT	0.64	0.57	1.74	1.01	0.86	1.98	2.17	2.77	3.36	3.92
Long-Term Debt to NOPAT	0.50	0.71	0.98	1.01	1.41	1.54	1.49	2.12	2.45	2.83
Altman Z-Score	16.66	19.92	13.56	23.53	19.15	11.62	9.69	7.21	6.19	4.58
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.05%	0.13%	0.37%	-0.86%	-0.25%	-0.14%	0.60%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.31	1.57	0.89	1.25	1.82	0.94	0.85	0.97	0.90	0.96
Quick Ratio	0.71	0.96	0.42	0.67	1.23	0.50	0.48	0.70	0.64	0.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	707	740	334	457	529	245	273	254	281	162
Operating Cash Flow to CapEx	768.26%	678.37%	364.82%	632.00%	605.90%	296.29%	345.64%	501.82%	545.86%	267.49%
Free Cash Flow to Firm to Interest Expense	22.64	17.79	8.39	15.34	15.96	7.89	7.85	6.83	8.77	5.52
Operating Cash Flow to Interest Expense	29.77	21.80	13.62	25.35	19.56	14.79	11.52	10.03	11.03	7.59
Operating Cash Flow Less CapEx to Interest Expense	25.90	18.59	9.89	21.34	16.34	9.80	8.18	8.03	9.01	4.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.19	1.22	1.30	1.36	1.31	1.43	1.36	1.21	1.18	1.12
Accounts Receivable Turnover	8.37	8.53	8.76	9.19	9.01	9.29	9.16	8.97	9.04	9.40
Inventory Turnover	3.98	3.93	4.28	5.54	5.61	5.65	5.76	5.41	4.61	4.08
Fixed Asset Turnover	5.51	5.42	5.44	5.63	4.97	4.96	5.42	5.35	5.14	5.03
Accounts Payable Turnover	13.51	13.32	12.04	13.91	15.48	14.70	14.24	13.72	14.20	14.61
Days Sales Outstanding (DSO)	43.59	42.77	41.68	39.72	40.51	39.29	39.86	40.70	40.38	38.82
Days Inventory Outstanding (DIO)	91.60	92.81	85.27	65.92	65.07	64.55	63.41	67.49	79.13	89.55
Days Payable Outstanding (DPO)	27.02	27.40	30.31	26.25	23.58	24.83	25.64	26.59	25.71	24.98
Cash Conversion Cycle (CCC)	108.17	108.19	96.64	79.39	81.99	79.00	77.64	81.59	93.80	103.39
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,175	1,978	1,845	1,469	1,157	1,075	867	735	704	744
Invested Capital Turnover	1.88	1.92	2.03	2.45	2.42	2.48	2.76	2.74	2.45	2.23
Increase / (Decrease) in Invested Capital	196	134	375	312	82	208	132	31	-39	49
Enterprise Value (EV)	34,434	46,592	35,022	56,612	43,164	23,298	16,918	14,429	11,327	7,461
Market Capitalization	33,854	46,098	33,786	55,833	42,639	22,400	16,041	13,639	10,514	6,633
Book Value per Share	$19.48	$17.87	$7.35	$8.14	$7.41	$2.07	($0.11)	($0.62)	($1.21)	($0.92)
Tangible Book Value per Share	$13.17	$12.45	$1.80	$2.73	$3.94	($1.41)	($3.08)	($3.41)	($3.71)	($3.51)
Total Capital	2,463	2,432	1,957	1,614	1,541	1,166	991	1,207	1,096	1,086
Total Debt	868	948	1,348	924	908	988	1,000	1,261	1,204	1,170
Total Long-Term Debt	450	623	694	775	858	699	601	606	593	597
Net Debt	579	494	1,236	779	525	897	876	789	812	828
Capital Expenditures (CapEx)	121	134	149	120	107	155	116	74	65	83
Debt-free, Cash-free Net Working Capital (DFCFNWC)	462	415	407	196	146	153	159	150	130	195
Debt-free Net Working Capital (DFNWC)	750	869	520	341	530	243	283	622	522	538
Net Working Capital (NWC)	332	544	-134	192	480	-46	-116	-33	-89	-35
Net Nonoperating Expense (NNE)	15	29	31	24	29	25	28	22	20	19
Net Nonoperating Obligations (NNO)	579	494	1,236	779	525	897	876	789	812	828
Total Depreciation and Amortization (D&A)	130	115	112	105	96	88	83	83	79	70
Debt-free, Cash-free Net Working Capital to Revenue	11.84%	11.33%	12.09%	6.10%	5.40%	6.35%	7.18%	7.64%	7.33%	12.19%
Debt-free Net Working Capital to Revenue	19.24%	23.73%	15.43%	10.59%	19.58%	10.10%	12.77%	31.61%	29.40%	33.58%
Net Working Capital to Revenue	8.52%	14.85%	-3.99%	5.97%	17.73%	-1.90%	-5.25%	-1.65%	-5.01%	-2.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$10.77	$10.17	$8.12	$8.74	$6.82	$4.97	$4.34	$3.00	$2.47	$2.07
Adjusted Weighted Average Basic Shares Outstanding	82.47M	83.07M	83.62M	85.20M	85.34M	86.12M	86.86M	87.77M	89.73M	92.60M
Adjusted Diluted Earnings per Share	$10.67	$10.06	$8.03	$8.60	$6.71	$4.89	$4.26	$2.94	$2.44	$2.05
Adjusted Weighted Average Diluted Shares Outstanding	83.25M	83.98M	84.60M	86.57M	86.72M	87.54M	88.47M	89.57M	90.88M	93.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.33M	83.09M	82.90M	84.25M	85.43M	85.33M	86.01M	87.12M	88.01M	89.64M
Normalized Net Operating Profit after Tax (NOPAT)	903	874	710	769	611	453	405	285	242	217
Normalized NOPAT Margin	23.16%	23.86%	21.08%	23.92%	22.56%	18.82%	18.29%	14.49%	13.61%	13.53%
Pre Tax Income Margin	28.48%	28.99%	25.54%	28.07%	24.46%	21.70%	20.68%	19.35%	18.13%	17.05%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	36.16	26.39	22.55	31.27	20.97	17.80	14.14	11.10	10.93	10.26
NOPAT to Interest Expense	28.93	21.01	17.81	25.80	18.44	14.58	11.65	7.67	7.54	7.22
EBIT Less CapEx to Interest Expense	32.28	23.17	18.82	27.26	17.74	12.81	10.81	9.10	8.91	7.42
NOPAT Less CapEx to Interest Expense	25.05	17.80	14.07	21.79	15.21	9.59	8.32	5.67	5.52	4.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.13%	0.00%	0.00%	0.00%	0.00%	2.13%	0.00%
Augmented Payout Ratio	94.27%	8.51%	120.71%	100.39%	31.40%	70.52%	97.95%	107.33%	139.07%	209.22%

This table displays calculated financial ratios and metrics derived from IDEXX Laboratories' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.56%	5.84%	6.56%	6.35%	7.10%	8.81%	8.78%	9.65%	7.61%	3.43%	3.85%
EBITDA Growth	6.61%	7.40%	11.09%	-8.64%	6.52%	7.75%	11.30%	56.38%	12.32%	12.50%	8.30%
EBIT Growth	5.88%	6.68%	10.39%	-10.92%	6.62%	8.29%	12.44%	65.38%	12.91%	13.72%	8.35%
NOPAT Growth	3.93%	10.81%	8.55%	-10.86%	6.30%	8.82%	15.29%	68.13%	12.41%	8.28%	4.63%
Net Income Growth	3.01%	11.12%	9.71%	-9.34%	10.06%	12.96%	17.29%	69.90%	10.36%	5.80%	3.29%
EPS Growth	5.34%	13.42%	10.67%	-8.61%	10.20%	12.68%	17.67%	71.15%	12.33%	9.04%	5.91%
Operating Cash Flow Growth	19.83%	4.87%	-19.22%	23.96%	7.98%	44.07%	44.14%	204.20%	60.33%	-17.40%	0.96%
Free Cash Flow Firm Growth	162.09%	-62.45%	800.69%	287.02%	153.79%	133.88%	103.56%	73.53%	34.81%	-34.59%	-4.00%
Invested Capital Growth	5.05%	9.91%	10.02%	6.34%	9.56%	7.26%	12.08%	15.99%	20.14%	25.55%	21.01%
Revenue Q/Q Growth	4.63%	-2.18%	-2.79%	4.10%	6.93%	-1.52%	-2.98%	4.83%	8.64%	-1.56%	-2.19%
EBITDA Q/Q Growth	18.69%	-12.61%	14.20%	-9.99%	19.57%	-9.61%	-6.09%	4.95%	20.95%	-6.63%	31.95%
EBIT Q/Q Growth	20.96%	-13.89%	15.20%	-11.76%	21.87%	-10.89%	-7.04%	5.62%	23.78%	-7.48%	36.73%
NOPAT Q/Q Growth	12.29%	-6.80%	14.35%	-13.14%	19.72%	-8.71%	-6.10%	3.58%	22.55%	-3.28%	36.94%
Net Income Q/Q Growth	12.27%	-7.17%	14.53%	-13.70%	21.11%	-8.34%	-5.35%	4.76%	24.30%	-4.83%	37.10%
EPS Q/Q Growth	12.98%	-6.43%	14.75%	-13.17%	21.65%	-8.70%	-5.24%	4.71%	24.39%	-4.65%	37.82%
Operating Cash Flow Q/Q Growth	-9.18%	19.06%	-11.37%	25.04%	-20.52%	-8.29%	36.00%	8.92%	6.05%	-8.24%	187.02%
Free Cash Flow Firm Q/Q Growth	474.90%	-35.46%	-52.81%	49.69%	-17.63%	1,448.06%	109.80%	56.95%	48.12%	-62.74%	27.19%
Invested Capital Q/Q Growth	2.28%	-0.40%	2.82%	0.30%	7.01%	-0.30%	-0.62%	3.33%	4.77%	4.17%	2.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.44%	59.80%	61.10%	61.70%	61.52%	58.36%	59.85%	60.71%	60.32%	58.53%	60.19%
EBITDA Margin	35.11%	30.95%	34.65%	29.49%	34.11%	30.51%	33.23%	34.34%	34.30%	30.81%	32.48%
Operating Margin	31.70%	27.42%	31.15%	26.29%	31.01%	27.21%	30.07%	31.38%	31.15%	27.34%	29.09%
EBIT Margin	31.70%	27.42%	31.15%	26.29%	31.01%	27.21%	30.07%	31.38%	31.15%	27.34%	29.09%
Profit (Net Income) Margin	24.31%	22.65%	23.87%	20.26%	24.44%	21.58%	23.18%	23.76%	23.78%	20.78%	21.50%
Tax Burden Percent	78.26%	84.31%	77.90%	78.48%	79.73%	81.16%	79.22%	78.42%	79.96%	80.77%	77.26%
Interest Burden Percent	97.96%	97.98%	98.36%	98.20%	98.84%	97.70%	97.31%	96.55%	95.47%	94.12%	95.65%
Effective Tax Rate	21.74%	15.69%	22.10%	21.52%	20.27%	18.84%	20.78%	21.58%	20.04%	19.23%	22.74%
Return on Invested Capital (ROIC)	44.94%	43.39%	44.77%	37.90%	45.48%	42.29%	45.52%	46.52%	48.27%	44.88%	46.42%
ROIC Less NNEP Spread (ROIC-NNEP)	44.18%	42.56%	44.15%	37.38%	45.14%	41.76%	44.93%	45.78%	47.28%	43.81%	45.60%
Return on Net Nonoperating Assets (RNNOA)	19.40%	14.83%	18.97%	20.22%	30.71%	34.51%	50.21%	63.98%	65.78%	67.97%	74.15%
Return on Equity (ROE)	64.34%	58.22%	63.74%	58.11%	76.19%	76.80%	95.73%	110.50%	114.04%	112.85%	120.57%
Cash Return on Invested Capital (CROIC)	37.09%	34.02%	32.74%	35.72%	34.73%	38.70%	34.28%	29.76%	23.18%	20.18%	24.02%
Operating Return on Assets (OROA)	37.96%	32.62%	37.21%	31.66%	37.49%	33.16%	37.68%	40.26%	39.57%	35.52%	38.66%
Return on Assets (ROA)	29.10%	26.94%	28.51%	24.40%	29.54%	26.30%	29.05%	30.49%	30.21%	27.00%	28.57%
Return on Common Equity (ROCE)	64.34%	58.22%	63.74%	58.11%	76.19%	76.80%	95.73%	110.50%	114.04%	112.85%	120.50%
Return on Equity Simple (ROE_SIMPLE)	61.81%	0.00%	53.54%	53.51%	55.23%	0.00%	63.41%	72.35%	83.13%	0.00%	140.68%
Net Operating Profit after Tax (NOPAT)	248	221	237	207	238	199	218	232	224	183	189
NOPAT Margin	24.81%	23.12%	24.27%	20.63%	24.72%	22.08%	23.82%	24.61%	24.91%	22.08%	22.47%
Net Nonoperating Expense Percent (NNEP)	0.76%	0.83%	0.62%	0.51%	0.34%	0.53%	0.59%	0.74%	0.99%	1.07%	0.82%
Return On Investment Capital (ROIC_SIMPLE)	10.37%	8.96%	-	-	-	8.19%	-	-	-	9.35%	-
Cost of Revenue to Revenue	37.56%	40.20%	38.90%	38.30%	38.48%	41.64%	40.15%	39.29%	39.68%	41.47%	39.81%
SG&A Expenses to Revenue	9.17%	10.60%	9.42%	15.67%	9.55%	9.65%	9.72%	9.50%	7.79%	10.02%	9.95%
R&D to Revenue	5.92%	6.05%	5.53%	5.53%	5.46%	5.75%	5.24%	4.93%	4.96%	5.24%	5.70%
Operating Expenses to Revenue	30.73%	32.38%	29.95%	35.41%	30.51%	31.15%	29.79%	29.32%	29.17%	31.19%	31.10%
Earnings before Interest and Taxes (EBIT)	317	262	304	264	299	245	275	296	280	227	245
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	351	295	338	296	329	275	304	324	309	255	273
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	23.59	21.22	25.70	25.46	28.58	31.05	27.98	38.11	49.29	55.50	56.98
Price to Tangible Book Value (P/TBV)	36.60	31.39	37.83	37.91	42.92	44.58	42.78	65.27	108.02	226.34	1,307.88
Price to Revenue (P/Rev)	8.69	8.69	10.82	10.63	12.04	12.59	10.12	11.86	12.08	10.03	8.12
Price to Earnings (P/E)	38.16	38.13	48.00	47.58	51.75	54.55	44.12	52.67	59.30	49.75	40.50
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.62%	2.62%	2.08%	2.10%	1.93%	1.83%	2.27%	1.90%	1.69%	2.01%	2.47%
Enterprise Value to Invested Capital (EV/IC)	15.70	15.83	19.30	19.20	21.44	23.55	18.64	21.33	22.02	18.99	16.05
Enterprise Value to Revenue (EV/Rev)	8.88	8.83	10.96	10.77	12.19	12.73	10.31	12.12	12.40	10.40	8.51
Enterprise Value to EBITDA (EV/EBITDA)	27.29	27.37	34.05	33.87	36.84	38.44	31.02	36.67	40.74	34.65	28.93
Enterprise Value to EBIT (EV/EBIT)	30.48	30.52	37.90	37.64	40.68	42.47	34.30	40.64	45.71	38.97	32.61
Enterprise Value to NOPAT (EV/NOPAT)	38.30	38.15	47.83	47.28	51.13	53.33	43.14	51.41	57.94	49.35	40.84
Enterprise Value to Operating Cash Flow (EV/OCF)	36.07	37.07	45.97	42.08	49.27	51.40	44.56	57.04	69.50	64.50	49.04
Enterprise Value to Free Cash Flow (EV/FCFF)	43.39	48.74	61.77	55.42	64.55	62.98	57.47	76.98	103.68	104.73	73.16
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.65	0.54	0.54	0.60	0.60	0.64	0.79	0.95	1.43	2.22	2.93
Long-Term Debt to Equity	0.31	0.28	0.32	0.33	0.40	0.42	0.48	0.64	0.83	1.14	1.60
Financial Leverage	0.44	0.35	0.43	0.54	0.68	0.83	1.12	1.40	1.39	1.55	1.63
Leverage Ratio	2.18	2.13	2.21	2.35	2.56	2.87	3.23	3.53	3.65	3.99	4.08
Compound Leverage Factor	2.13	2.08	2.17	2.31	2.53	2.80	3.14	3.41	3.48	3.76	3.90
Debt to Total Capital	39.37%	35.23%	35.07%	37.42%	37.61%	38.97%	43.99%	48.64%	58.85%	68.90%	74.54%
Short-Term Debt to Total Capital	20.54%	16.96%	14.01%	16.64%	12.92%	13.36%	17.27%	15.92%	24.78%	33.42%	33.85%
Long-Term Debt to Total Capital	18.83%	18.26%	21.06%	20.78%	24.69%	25.61%	26.72%	32.72%	34.07%	35.48%	40.69%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.63%	64.77%	64.93%	62.58%	62.39%	61.03%	56.01%	51.36%	41.15%	31.10%	25.46%
Debt to EBITDA	0.73	0.69	0.71	0.78	0.77	0.78	0.85	0.89	1.15	1.33	1.42
Net Debt to EBITDA	0.61	0.46	0.46	0.45	0.45	0.41	0.58	0.78	1.04	1.22	1.32
Long-Term Debt to EBITDA	0.35	0.36	0.42	0.44	0.50	0.51	0.52	0.60	0.67	0.69	0.77
Debt to NOPAT	1.03	0.96	0.99	1.10	1.07	1.08	1.19	1.25	1.64	1.90	2.00
Net Debt to NOPAT	0.85	0.64	0.64	0.63	0.62	0.57	0.80	1.09	1.49	1.74	1.86
Long-Term Debt to NOPAT	0.49	0.50	0.60	0.61	0.70	0.71	0.72	0.84	0.95	0.98	1.09
Altman Z-Score	15.65	15.80	18.14	16.67	18.63	19.06	15.72	17.73	16.13	12.76	10.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.16	1.31	1.42	1.37	1.57	1.57	1.43	1.33	1.08	0.89	0.89
Quick Ratio	0.61	0.71	0.81	0.84	0.95	0.96	0.81	0.67	0.52	0.42	0.41
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	141	24	38	80	54	65	4.21	-43	-100	-192	-118
Operating Cash Flow to CapEx	792.52%	895.66%	783.51%	745.57%	655.98%	767.45%	799.06%	729.21%	465.47%	352.29%	501.53%
Free Cash Flow to Firm to Interest Expense	18.35	3.26	4.93	9.92	6.79	7.03	0.49	-4.08	-7.60	-14.20	-10.75
Operating Cash Flow to Interest Expense	31.04	34.95	28.59	30.66	25.10	26.97	31.51	19.00	14.01	12.80	17.18
Operating Cash Flow Less CapEx to Interest Expense	27.12	31.04	24.94	26.55	21.28	23.45	27.56	16.40	11.00	9.17	13.76
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.20	1.19	1.19	1.20	1.21	1.22	1.25	1.28	1.27	1.30	1.33
Accounts Receivable Turnover	7.60	8.37	7.98	7.60	7.82	8.53	8.53	8.03	8.09	8.76	8.73
Inventory Turnover	3.87	3.98	3.85	3.87	3.80	3.93	3.84	3.87	3.99	4.28	4.45
Fixed Asset Turnover	5.51	5.51	5.47	5.44	5.42	5.42	5.52	5.50	5.45	5.44	5.63
Accounts Payable Turnover	12.82	13.51	13.53	13.31	12.63	13.32	12.92	11.98	11.59	12.04	13.86
Days Sales Outstanding (DSO)	48.03	43.59	45.76	48.00	46.70	42.77	42.77	45.43	45.12	41.68	41.79
Days Inventory Outstanding (DIO)	94.28	91.60	94.70	94.40	96.07	92.81	94.97	94.41	91.44	85.27	82.08
Days Payable Outstanding (DPO)	28.47	27.02	26.97	27.42	28.91	27.40	28.25	30.48	31.50	30.31	26.33
Cash Conversion Cycle (CCC)	113.83	108.17	113.49	114.98	113.87	108.19	109.49	109.36	105.06	96.64	97.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,224	2,175	2,183	2,124	2,117	1,978	1,985	1,997	1,933	1,845	1,771
Invested Capital Turnover	1.81	1.88	1.85	1.84	1.84	1.92	1.91	1.89	1.94	2.03	2.07
Increase / (Decrease) in Invested Capital	107	196	199	127	185	134	214	275	324	375	307
Enterprise Value (EV)	34,930	34,434	42,148	40,780	45,390	46,592	36,986	42,591	42,550	35,022	28,419
Market Capitalization	34,154	33,854	41,583	40,237	44,842	46,098	36,299	41,688	41,458	33,786	27,124
Book Value per Share	$17.80	$19.48	$19.66	$19.13	$18.88	$17.87	$15.63	$13.18	$10.15	$7.35	$5.72
Tangible Book Value per Share	$11.47	$13.17	$13.35	$12.85	$12.57	$12.45	$10.22	$7.70	$4.63	$1.80	$0.25
Total Capital	2,388	2,463	2,492	2,525	2,515	2,432	2,316	2,130	2,044	1,957	1,870
Total Debt	940	868	874	945	946	948	1,019	1,036	1,203	1,348	1,394
Total Long-Term Debt	450	450	525	525	621	623	619	697	696	694	761
Net Debt	776	579	565	543	548	494	687	903	1,091	1,236	1,295
Capital Expenditures (CapEx)	30	29	28	33	30	33	34	27	40	49	38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	508	462	465	430	473	415	482	501	479	407	403
Debt-free Net Working Capital (DFNWC)	672	750	774	832	870	869	814	634	590	520	502
Net Working Capital (NWC)	181	332	425	412	545	544	414	295	84	-134	-131
Net Nonoperating Expense (NNE)	5.05	4.47	3.88	3.72	2.77	4.57	5.86	8.01	10	11	8.22
Net Nonoperating Obligations (NNO)	776	579	565	543	548	494	687	903	1,091	1,236	1,295
Total Depreciation and Amortization (D&A)	34	34	34	32	30	30	29	28	28	29	29
Debt-free, Cash-free Net Working Capital to Revenue	12.92%	11.84%	12.09%	11.37%	12.69%	11.33%	13.44%	14.27%	13.96%	12.09%	12.06%
Debt-free Net Working Capital to Revenue	17.09%	19.24%	20.12%	21.98%	23.36%	23.73%	22.69%	18.05%	17.21%	15.43%	15.03%
Net Working Capital to Revenue	4.61%	8.52%	11.04%	10.88%	14.63%	14.85%	11.54%	8.40%	2.44%	-3.99%	-3.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.98	$2.64	$2.83	$2.46	$2.84	$2.34	$2.55	$2.70	$2.58	$2.08	$2.17
Adjusted Weighted Average Basic Shares Outstanding	81.32M	82.47M	82.30M	82.63M	83.10M	83.07M	83.10M	83.09M	82.99M	83.62M	83.25M
Adjusted Diluted Earnings per Share	$2.96	$2.62	$2.80	$2.44	$2.81	$2.31	$2.53	$2.67	$2.55	$2.05	$2.15
Adjusted Weighted Average Diluted Shares Outstanding	81.92M	83.25M	83.06M	83.39M	83.96M	83.98M	83.99M	83.98M	83.96M	84.60M	84.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	80.42M	81.33M	81.88M	82.31M	82.59M	83.09M	83.05M	83.01M	83.00M	82.90M	82.82M
Normalized Net Operating Profit after Tax (NOPAT)	248	221	237	207	238	199	218	232	224	183	189
Normalized NOPAT Margin	24.81%	23.12%	24.27%	20.63%	24.72%	22.08%	23.82%	24.61%	24.91%	22.08%	22.47%
Pre Tax Income Margin	31.06%	26.87%	30.64%	25.81%	30.65%	26.58%	29.26%	30.30%	29.74%	25.73%	27.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	41.29	34.90	39.48	32.57	37.79	26.48	31.84	28.09	21.36	16.72	22.26
NOPAT to Interest Expense	32.31	29.42	30.76	25.56	30.13	21.49	25.22	22.03	17.08	13.51	17.20
EBIT Less CapEx to Interest Expense	37.37	31.00	35.83	28.46	33.96	22.96	27.89	25.49	18.35	13.09	18.83
NOPAT Less CapEx to Interest Expense	28.40	25.52	27.11	21.45	26.30	17.97	21.28	19.42	14.07	9.87	13.77
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	121.03%	94.27%	72.48%	52.29%	26.16%	8.51%	13.26%	31.17%	79.15%	120.71%	147.90%

Frequently Asked Questions About IDEXX Laboratories' Financials

When does IDEXX Laboratories's fiscal year end?

According to the most recent income statement we have on file, IDEXX Laboratories' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has IDEXX Laboratories' net income changed over the last 9 years?

IDEXX Laboratories' net income appears to be on an upward trend, with a most recent value of $887.87 million in 2024, rising from $192.14 million in 2015. The previous period was $845.04 million in 2023. View IDEXX Laboratories' forecast to see where analysts expect IDEXX Laboratories to go next.

What is IDEXX Laboratories's operating income?

IDEXX Laboratories's total operating income in 2024 was $1.13 billion, based on the following breakdown:

Total Gross Profit: $2.38 billion
Total Operating Expenses: $1.25 billion

How has IDEXX Laboratories revenue changed over the last 9 years?

Over the last 9 years, IDEXX Laboratories' total revenue changed from $1.60 billion in 2015 to $3.90 billion in 2024, a change of 143.3%.

How much debt does IDEXX Laboratories have?

IDEXX Laboratories' total liabilities were at $1.70 billion at the end of 2024, a 4.4% decrease from 2023, and a 8.9% increase since 2015.

How much cash does IDEXX Laboratories have?

In the past 9 years, IDEXX Laboratories' cash and equivalents has ranged from $90.33 million in 2019 to $453.93 million in 2023, and is currently $288.27 million as of their latest financial filing in 2024.

How has IDEXX Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, IDEXX Laboratories' book value per share changed from -0.92 in 2015 to 19.48 in 2024, a change of -2,206.7%.

Related Companies

This page (NASDAQ:IDXX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Financials

Frequently Asked Questions About IDEXX Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEXX Laboratories (IDXX) Financials

Annual Income Statements for IDEXX Laboratories

Quarterly Income Statements for IDEXX Laboratories

Annual Cash Flow Statements for IDEXX Laboratories

Quarterly Cash Flow Statements for IDEXX Laboratories

Annual Balance Sheets for IDEXX Laboratories

Quarterly Balance Sheets for IDEXX Laboratories

Annual Metrics And Ratios for IDEXX Laboratories

Quarterly Metrics And Ratios for IDEXX Laboratories

Frequently Asked Questions About IDEXX Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools